Detalles de la búsqueda
1.
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks).
Breast Cancer Res Treat
; 2024 May 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38767786
2.
Current Status of Advance Care Planning and End-of-life Communication for Patients with Advanced and Metastatic Breast Cancer.
Oncologist
; 26(4): e686-e693, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33321004
3.
Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial.
Breast Cancer Res Treat
; 188(1): 117-131, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33763789
4.
Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917).
BMC Cancer
; 21(1): 795, 2021 Jul 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34238257
5.
Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer.
BMC Cancer
; 21(1): 1269, 2021 Nov 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-34819039
6.
A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.
Breast Cancer Res Treat
; 180(1): 135-146, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31953696
7.
Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis.
Breast Cancer Res Treat
; 167(1): 81-87, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28895005
8.
Gemcitabine and Vinorelbine Combination Chemotherapy in Taxane-Pretreated Patients with Metastatic Breast Cancer: A Phase II Study of the Kinki Multidisciplinary Breast Oncology Group (KMBOG) 1015.
Chemotherapy
; 62(5): 307-313, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28605730
9.
Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence.
Breast Cancer Res
; 18(1): 73, 2016 07 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27368476
10.
[A Case of Recurrent Breast Cancer with Adrenal Metastasis Resected Using Laparoscopic Surgery].
Gan To Kagaku Ryoho
; 43(12): 2035-2037, 2016 Nov.
Artículo
en Japonés
| MEDLINE | ID: mdl-28133213
11.
Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis.
Breast Cancer Res Treat
; 149(1): 277-84, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25528021
12.
Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis.
Breast Cancer Res Treat
; 147(1): 103-12, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25106661
13.
[Therapeutic effect of rebamipide for oral mucositis associated with FEC therapy for breast cancer].
Gan To Kagaku Ryoho
; 41(11): 1407-12, 2014 Nov.
Artículo
en Japonés
| MEDLINE | ID: mdl-25434444
14.
[Effect of oral dexamethasone given 24 hours previously on docetaxel-induced edema: a retrospective study].
Gan To Kagaku Ryoho
; 41(2): 211-4, 2014 Feb.
Artículo
en Japonés
| MEDLINE | ID: mdl-24743199
15.
Overall survival in Japanese patients with ER+/HER2- advanced breast cancer treated with first-line palbociclib plus letrozole.
Breast Cancer
; 31(1): 53-62, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37882974
16.
Genomic Landscape of Circulating Tumor DNA in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Treated With Abemaciclib: Data From the SCRUM-Japan Cancer Genome Screening Project.
JCO Precis Oncol
; 8: e2300647, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38635933
17.
Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study.
Breast Cancer
; 2024 Apr 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38642245
18.
Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316).
Breast Cancer
; 30(6): 943-951, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37486454
19.
Pembrolizumab plus chemotherapy in Japanese patients with triple-negative breast cancer: Results from KEYNOTE-355.
Cancer Med
; 12(9): 10280-10293, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36916728
20.
Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial).
J Immunother Cancer
; 11(9)2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37709297